Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.56 |
| ▸ | TLR2 | O60603 | 1/20 | 0.56 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.56 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30331767 | 1.00 | ERN1 (0.56) | ERN1TLR2TLR1TLR6ACHE | |
| SCHEMBL870959 | 0.85 | ALDH1A1 (0.55) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL11534206 | 0.84 | ERN1 (0.50) | ERN1TLR2TLR1TLR6ACHE | |
| SCHEMBL3248320 | 0.84 | ACHE (0.54) | ERN1TLR2TLR1TLR6ACHE | |
| SCHEMBL12587484 | 0.84 | ACHE (0.45) | ACHEALDH1A1LMNAMAPK1KDM4E | |
| SCHEMBL3864807 | 0.84 | ERN1 (0.68) | ERN1TLR2TLR1TLR6ACHE | |
| Benzene SCHEMBL3155472 | 0.83 | ALDH1A1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL1959471 | 0.83 | ERN1 (0.53) | ERN1TLR2TLR1TLR6ACHE | |
| SCHEMBL544041 | 0.82 | ACHE (0.69) | ACHEALDH1A1LMNAMAPK1CYP1A2 | |
| SCHEMBL5241671 | 0.82 | MAPK1 (0.57) | ERN1TLR2TLR1TLR6ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105307638-A | Photosensitive particles and application thereof in photodynamic therapy and development | XUE FUSHENG | 2016-02-03 | — | — | CN | disclosed |
| US-8012964-B2 | 9-substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| CN-100439331-C | Intermediate of anti-AIDS medicine 'Nelfinavir' and its syntesizing process and application | SHANGHAI INST ORGANIC CHEM (CN) | 2008-12-03 | — | — | CN | disclosed |
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050215801-A1 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates | KANEKA CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1553093-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE 1-SUBSTITUTED AMINO-2,3-EPOXYPROPANES, INTERMEDIATES FOR THE SYNTHESIS THEREOF AND PROCESS FOR PREPARATION OF THE INTERMEDIATES | KANEKA CORPORATION (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | EXITHERA PHARMACEUTICALS LLC | 2005-06-30 | — | — | US | disclosed |
| WO-2004103270-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES LLC (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004089297-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES, LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-6605721-B2 | Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2003-08-12 | — | — | US | disclosed |
| US-6512135-B2 | 2-methyl-3-(protected hydroxy) benzyl chloride; use making nelfinavir mesylate | AGOURON PHARMACEUTICALS, INC. | 2003-01-28 | — | — | US | disclosed |
| US-6407285-B1 | AS CHEMICAL INTERMEDIATE TO PREPARE NELFINAVIR COMPOUNDS | AGOURON PHARMACEUTICALS, INC. | 2002-06-18 | — | — | US | disclosed |
| US-6303786-B1 | SALT FORMATION IN A SOLVENT | AGOURON PHARMACEUTICALS, INC. | 2001-10-16 | — | — | US | disclosed |
| EP-0927165-A2 | INTERMEDIATES FOR MAKING HIV-PROTEASE INHIBITORS AND METHODS OF MAKING HIV-PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998009951-A2 | INTERMEDIATES FOR MAKING HIV-PROTEASE INHIBITORS AND METHODS OF MAKING HIV-PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | SERPINC1, F11, F13B | ERN1 2398/4885TLR2 3685/4885TLR1 4153/4885 |
| US-20050215801-A1 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates | OXER1, RCC2, CBR3 | ERN1 1143/4885TLR2 2792/4885TLR1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.